MC

481.7

+1.31%↑

BNP

78.97

+0.71%↑

DB1.DE

252.1

-0.67%↓

NDA.FI

12.84

+0.55%↑

BKT

12.35

-0.12%↓

MC

481.7

+1.31%↑

BNP

78.97

+0.71%↑

DB1.DE

252.1

-0.67%↓

NDA.FI

12.84

+0.55%↑

BKT

12.35

-0.12%↓

MC

481.7

+1.31%↑

BNP

78.97

+0.71%↑

DB1.DE

252.1

-0.67%↓

NDA.FI

12.84

+0.55%↑

BKT

12.35

-0.12%↓

MC

481.7

+1.31%↑

BNP

78.97

+0.71%↑

DB1.DE

252.1

-0.67%↓

NDA.FI

12.84

+0.55%↑

BKT

12.35

-0.12%↓

MC

481.7

+1.31%↑

BNP

78.97

+0.71%↑

DB1.DE

252.1

-0.67%↓

NDA.FI

12.84

+0.55%↑

BKT

12.35

-0.12%↓

Search

Sartorius Stedim Biotech.

Chiusa

SettoreFinanza

179.1 -0.03

Panoramica

Variazione del prezzo dell'azione

24h

Corrente

Minimo

177.8

Massimo

181.85

Metriche Chiave

By Trading Economics

Entrata

75M

115M

Vendite

-6.7M

745M

P/E

Media del settore

90.261

24.782

EPS

1.16

Margine di Profitto

15.498

Dipendenti

9,961

EBITDA

124M

256M

Raccomandazioni

By TipRanks

Raccomandazioni

Fortemente da comprare

Previsioni per 12 mesi

+27.75% upside

Dividendi

By Dow Jones

Utili prossimi

16 ott 2025

Statistiche di mercato

By TradingEconomics

Capitalizzazione di Mercato

3.3B

20B

Apertura precedente

179.13

Chiusura precedente

179.1

Notizie sul Sentiment di mercato

By Acuity

14%

86%

27 / 536 Classifica in Finance

Punteggio Tecnico

By Trading Central

Fiducia

Bullish Evidence

Sartorius Stedim Biotech. Grafico

Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.

Notizie correlate

29 lug 2025, 23:57 UTC

Acquisizioni, Fusioni, Takeovers

EQT: To Spend Y407.82B for Tender Offer

29 lug 2025, 23:56 UTC

Acquisizioni, Fusioni, Takeovers

EQT: Tender Offer Price Is Y5,700 a Share

29 lug 2025, 23:54 UTC

Acquisizioni, Fusioni, Takeovers

EQT To Start Tender Offer for Fujitec

29 lug 2025, 23:50 UTC

Discorsi di Mercato

Nikkei May Fall Amid Uncertainty Over Earnings, Domestic Politics -- Market Talk

29 lug 2025, 23:36 UTC

Discorsi di Mercato

Gold Steady Ahead of FOMC Decision -- Market Talk

29 lug 2025, 22:57 UTC

Discorsi di Mercato

Perseus May Step Up Capital Management at FY 2025 Result -- Market Talk

29 lug 2025, 22:50 UTC

Discorsi di Mercato

Mondelez Warns of Price Increases in North America -- Market Talk

29 lug 2025, 22:44 UTC

Acquisizioni, Fusioni, Takeovers

St Barbara: Potential Divestment of Nova Scotia Ops to be Weighed in 1Q FY26

29 lug 2025, 22:41 UTC

Acquisizioni, Fusioni, Takeovers

St Barbara FY25 All-in Sustaining Cost A$4,582/Oz

29 lug 2025, 22:41 UTC

Acquisizioni, Fusioni, Takeovers

St Barbara 4Q All-in Sustaining Cost A$4,613/Oz

29 lug 2025, 22:35 UTC

Utili

IGO Maintains Nova Life of Mine Production Guidance

29 lug 2025, 22:35 UTC

Utili

IGO Expects FY 2026 Greenbushes Output of 1.50 Million-1.65 Million Tons

29 lug 2025, 22:35 UTC

Utili

IGO Expects FY 2026 Greenbushes Cash Costs of A$310-A$360/Ton

29 lug 2025, 22:34 UTC

Utili

IGO Expects Train 1 of Kwinana Refinery to Be Fully Impaired

29 lug 2025, 22:34 UTC

Utili

IGO Expects to Impair Kwinana Refinery Assets by A$70 Million-A$90 Million

29 lug 2025, 22:34 UTC

Discorsi di Mercato
Utili

Mondelez Snack Demand Holding Up Better in Europe Than U.S. -- Market Talk

29 lug 2025, 22:33 UTC

Utili

IGO Had A$279.7 Million of Cash at End-June

29 lug 2025, 22:33 UTC

Utili

IGO 4Q Underlying Free Cash A$2.4 Million

29 lug 2025, 22:33 UTC

Utili

IGO FY Sales Revenue A$512.5 Million

29 lug 2025, 22:33 UTC

Utili

IGO 4Q Sales Revenue A$126.9 Million, Up 15% on 3Q

29 lug 2025, 22:32 UTC

Utili

IGO FY Nickel Production 17,173 Tons

29 lug 2025, 22:32 UTC

Utili

IGO 4Q Nickel Production 5,107 Tons, Up 22% on 3Q

29 lug 2025, 22:32 UTC

Utili

IGO 4Q Lithium Hydroxide Production 2,126 Tons, Up 36% on 3Q

29 lug 2025, 22:31 UTC

Discorsi di Mercato
Utili

Global Equities Roundup: Market Talk

29 lug 2025, 22:31 UTC

Discorsi di Mercato
Utili

Mondelez Sees Consumers Trading Down, Buying in Bulk -- Market Talk

29 lug 2025, 22:31 UTC

Utili

IGO 4Q Spodumene Cash Cost A$366/Ton, Up 7% on 3Q

29 lug 2025, 22:31 UTC

Utili

IGO FY Spodumene Production 1.48 Million Tons

29 lug 2025, 22:30 UTC

Utili

IGO 4Q Spodumene Production 340,000 Tons, Flat on 3Q

29 lug 2025, 22:30 UTC

Utili

IGO 4Q Underlying Ebitda A$62 Million

29 lug 2025, 22:22 UTC

Utili

Starbucks Abandons Mobile Order, Pickup-Only Stores -- WSJ

Confronto tra pari

Modifica del prezzo

Sartorius Stedim Biotech. Previsione

Obiettivo di Prezzo

By TipRanks

27.75% in crescita

Previsioni per 12 mesi

Media 229.38 EUR  27.75%

Alto 245 EUR

Basso 210 EUR

Basato su 8 analisti di Wall Street che offrono Obiettivi di Prezzo a 12 mesi per Sartorius Stedim Biotech. - Dist negli ultimi 3 mesi.

Consenso sulla valutazione

By TipRanks

Fortemente da comprare

8 ratings

6

Acquista

2

Mantieni

0

Vendi

Punteggio Tecnico

By Trading Central

202.7 / 211.7Supporto e resistenza

A breve termine

Bullish Evidence

A termine intermedio

Strong Bullish Evidence

A lungo termine

Strong Bullish Evidence

Sentiment

By Acuity

27 / 536 Classifica in Finanza

Notizie sul Sentiment di mercato

Prove rialziste molto forti

Volatilità

Sotto la media

Volume delle notizie (RCV)

Sopra la media

Notizie finanziarie

Spese di vendita e di amministrazione

Spese operative

Utile prima delle imposte

Vendite

Costo delle vendite

Utile lordo sulle vendite

Interessi passivi sul debito

EBITDA

Utile operativo

$

Chi Siamo Sartorius Stedim Biotech.

Sartorius Stedim Biotech S.A. engages in the production and sale of instruments and consumables for the biopharmaceutical industry worldwide. The company offers various products, such as cell lines; cell culture media; bioreactors; advanced therapies; and a range of products for separation, purification, and concentration processes, as well as products and systems for storage and transportation of intermediate and finished biological products. It also provides cell cultivation, fermentation, separation, purification, and fluid management services; biolayer interferometry instruments; microbiology enumeration, sterility testing, and air monitoring instruments; pipette products; sensors and analyzers; biomolecule analysis tools; flow cytometry; batch and intensified chromatography systems; lab data and fleet management software; live cell imaging and analysis; surface plasmon resonance solutions; and weighing products. In addition, the company offers data analytics software for modeling and optimizing processes of biopharmaceutical development and production; process automation platform and software; and develops and produces transfection, as well as other DNA/RNA delivery reagents and plasmid DNA. It serves manufacturers of medications, vaccines, foods, and chemicals, as well as research and development laboratories. The company was incorporated in 1978 and is headquartered in Aubagne, France. As of December 31, 2023, Sartorius Stedim Biotech S.A. operates as a subsidiary of Sartorius AG.